Supplementary Data — SA58 reduced COVID-19 risk: real-time meta analysis of 3 studies

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang 34% 0.66 [0.55-0.80] cases 44/70 343/362 Improvement, RR [CI] Treatment Control Song (SB RCT) 81% 0.19 [0.08-0.48] symp. case 824 (n) 299 (n) Song (SB RCT) 62% 0.38 [0.23-0.62] cases 824 (n) 299 (n) Si 78% 0.22 [0.10-0.48] cases 3,368 (all patients) SA58 COVID-19 outcomes c19early.org November 2025 Favors SA58 Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.